Implications of all the available evidence
We here provide a comprehensive, longitudinal assessment of immunogenicity-related responses in a broad range of immunocompromised patient groups. The study allows temporal as well as comparative assessments across many patient groups in a real-world clinical study setting. The findings show that several immunocompromised patient groups need additional booster vaccine doses compared to healthy controls to reach similar levels of immunogenicity. In parallel, subgroups of non- or weak-responders are identified.